Historical shareholding details of
AllianceBernstein L.P.
holdings in Novo Nordisk - ADR (NVO)
Monthly changes of
AllianceBernstein L.P.
shareholding in Novo Nordisk - ADR
over the previous
months
|
Month
|
Name |
Total no. shares held |
Percent Holding |
|
Mar 31, 2025
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Feb 28, 2025
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Jan 31, 2025
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Dec 31, 2024
|
Alliancebernstein L.P.
|
23,014
|
0.00%
|
|
Dec 31, 2024
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Nov 30, 2024
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Oct 31, 2024
|
Alliancebernstein L.P.
|
237
|
0.00%
|
|
|
|
Sep 30, 2024
|
Alliancebernstein L.P.
|
23,490
|
0.00%
|
|
|
|
Aug 31, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Jul 31, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Jun 30, 2024
|
Alliancebernstein L.P.
|
58,022
|
0.00%
|
|
Jun 30, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
May 31, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Apr 30, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Mar 31, 2024
|
Alliancebernstein L.P.
|
39,662
|
0.00%
|
|
Mar 31, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Feb 29, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Jan 31, 2024
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Dec 31, 2023
|
Alliancebernstein L.P.
|
34,590
|
0.00%
|
|
Dec 31, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Nov 30, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Oct 31, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Sep 30, 2023
|
Alliancebernstein L.P.
|
28,456
|
0.00%
|
|
Sep 30, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Aug 31, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Jul 31, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
Jun 30, 2023
|
Alliancebernstein L.P.
|
58,754
|
0.00%
|
|
Jun 30, 2023
|
Alliancebernstein L.P.
|
0
|
0.00%
|
|
|
|
May 31, 2023
|
Alliancebernstein L.P.
|
30,671
|
0.00%
|
|
|
|
Mar 31, 2023
|
Alliancebernstein L.P.
|
13,165
|
0.00%
|
View all ownership details of Novo Nordisk - ADR